Cargando…
Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test
Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. Accurate prediction of preeclampsia risk would enable more effective, risk-based prenatal care pathways. Current risk assessment algorithms depend on clinical risk factors largely unavailable for first-time pregn...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769282/ https://www.ncbi.nlm.nih.gov/pubmed/33370367 http://dx.doi.org/10.1371/journal.pone.0244369 |
_version_ | 1783629289403449344 |
---|---|
author | Kenny, Louise C. Thomas, Grégoire Poston, Lucilla Myers, Jenny E. Simpson, Nigel A. B. McCarthy, Fergus P. Brown, Leslie W. Bond, Alison E. Tuytten, Robin Baker, Philip N. |
author_facet | Kenny, Louise C. Thomas, Grégoire Poston, Lucilla Myers, Jenny E. Simpson, Nigel A. B. McCarthy, Fergus P. Brown, Leslie W. Bond, Alison E. Tuytten, Robin Baker, Philip N. |
author_sort | Kenny, Louise C. |
collection | PubMed |
description | Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. Accurate prediction of preeclampsia risk would enable more effective, risk-based prenatal care pathways. Current risk assessment algorithms depend on clinical risk factors largely unavailable for first-time pregnant women. Delivering accurate preeclampsia risk assessment to this cohort of women, therefore requires for novel biomarkers. Here, we evaluated the relevance of metabolite biomarker candidates for their selection into a prototype rapid, quantitative Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) based clinical screening assay. First, a library of targeted LC-MS/MS assays for metabolite biomarker candidates was developed, using a medium-throughput translational metabolomics workflow, to verify biomarker potential in the Screening-for-Pregnancy-Endpoints (SCOPE, European branch) study. A variable pre-selection step was followed by the development of multivariable prediction models for pre-defined clinical use cases, i.e., prediction of preterm preeclampsia risk and of any preeclampsia risk. Within a large set of metabolite biomarker candidates, we confirmed the potential of dilinoleoyl-glycerol and heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine to effectively complement Placental Growth Factor, an established preeclampsia biomarker, for the prediction of preeclampsia risk in first-time pregnancies without overt risk factors. These metabolites will be considered for integration in a prototype rapid, quantitative LC-MS/MS assay, and subsequent validation in an independent cohort. |
format | Online Article Text |
id | pubmed-7769282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-77692822021-01-08 Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test Kenny, Louise C. Thomas, Grégoire Poston, Lucilla Myers, Jenny E. Simpson, Nigel A. B. McCarthy, Fergus P. Brown, Leslie W. Bond, Alison E. Tuytten, Robin Baker, Philip N. PLoS One Research Article Preeclampsia remains a leading cause of maternal and perinatal morbidity and mortality. Accurate prediction of preeclampsia risk would enable more effective, risk-based prenatal care pathways. Current risk assessment algorithms depend on clinical risk factors largely unavailable for first-time pregnant women. Delivering accurate preeclampsia risk assessment to this cohort of women, therefore requires for novel biomarkers. Here, we evaluated the relevance of metabolite biomarker candidates for their selection into a prototype rapid, quantitative Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) based clinical screening assay. First, a library of targeted LC-MS/MS assays for metabolite biomarker candidates was developed, using a medium-throughput translational metabolomics workflow, to verify biomarker potential in the Screening-for-Pregnancy-Endpoints (SCOPE, European branch) study. A variable pre-selection step was followed by the development of multivariable prediction models for pre-defined clinical use cases, i.e., prediction of preterm preeclampsia risk and of any preeclampsia risk. Within a large set of metabolite biomarker candidates, we confirmed the potential of dilinoleoyl-glycerol and heptadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine to effectively complement Placental Growth Factor, an established preeclampsia biomarker, for the prediction of preeclampsia risk in first-time pregnancies without overt risk factors. These metabolites will be considered for integration in a prototype rapid, quantitative LC-MS/MS assay, and subsequent validation in an independent cohort. Public Library of Science 2020-12-28 /pmc/articles/PMC7769282/ /pubmed/33370367 http://dx.doi.org/10.1371/journal.pone.0244369 Text en © 2020 Kenny et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Kenny, Louise C. Thomas, Grégoire Poston, Lucilla Myers, Jenny E. Simpson, Nigel A. B. McCarthy, Fergus P. Brown, Leslie W. Bond, Alison E. Tuytten, Robin Baker, Philip N. Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test |
title | Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test |
title_full | Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test |
title_fullStr | Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test |
title_full_unstemmed | Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test |
title_short | Prediction of preeclampsia risk in first time pregnant women: Metabolite biomarkers for a clinical test |
title_sort | prediction of preeclampsia risk in first time pregnant women: metabolite biomarkers for a clinical test |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769282/ https://www.ncbi.nlm.nih.gov/pubmed/33370367 http://dx.doi.org/10.1371/journal.pone.0244369 |
work_keys_str_mv | AT kennylouisec predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT thomasgregoire predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT postonlucilla predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT myersjennye predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT simpsonnigelab predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT mccarthyfergusp predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT brownlesliew predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT bondalisone predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT tuyttenrobin predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT bakerphilipn predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest AT predictionofpreeclampsiariskinfirsttimepregnantwomenmetabolitebiomarkersforaclinicaltest |